NYSE:NVS

Uncovering Sickle Cell Disease

Article

Every day, people endure the painful and life-threatening symptoms of sickle cell disease in the shadows because of fear, stigma,and isolation.1,2,3

New Public-Private Partnership to Strengthen Primary Healthcare in Vietnam

The Working Group for Primary Healthcare Transformation should complement the government’s efforts to strengthen primary healthcare to achieve Universal Health Coverage (UHC) in Vietnam.
Press Release

HANOI, Vietnam, May 21, 2019 /3BL Media/– A new public-private partnership, comprising the Vietnamese Ministry of Health, and three other founding members, i.e. World Economic Forum (WEF), Harvard Medical School Center for Primary Care and Novartis could transform primary healthcare in Vietnam. As announced by the Vietnamese Ministry of Health, this innovative public-private partnership will help deliver on the Ministry of Health’s objectives the Vietnamese Ministry of Health by strengthening existing primary care demonstration projects in 30 provinces.

Europe-Africa Partnership Spearheads Development of Next-generation Antimalarial Drug

Summary: 
  • The European & Developing Countries Clinical Trials Partnership (EDCTP) grants €10 million over five years to “WANECAM 2” a unique collaboration between antimalarial drug researchers in Africa and Europe from ten academic institutions, a pharmaceutical company, Novartis, and a not-for-profit product development partnership (PDP), Medicines for Malaria Venture.
  • The grant will support African trials of a novel antimalarial combination comprising KAF156 (ganaplacide) and lumefantrine in a new once-daily formulation. KAF156 has demonstrated the potential to treat resistant malaria and to be administered as a single dose.
  • The grant will also help to build and strengthen research capabilities in the four participating African countries: Burkina Faso, Gabon, Mali and Niger.
Press Release
  • The European & Developing Countries Clinical Trials Partnership (EDCTP) grants €10 million over five years to “WANECAM 2” a unique collaboration between antimalarial drug researchers in Africa and Europe from ten academic institutions, a pharmaceutical company, Novartis, and a not-for-profit product development partnership (PDP), Medicines for Malaria Venture.
  • The grant will support African trials of a novel antimalarial combination comprising KAF156 (ganaplacide) and lumefantrine in a new once-daily formulation. KAF156 has demonstrated the potential to treat resistant malaria and to be administered as a single dose.
  • The grant will also help to build and strengthen research capabilities in the four participating African countries: Burkina Faso, Gabon, Mali and Niger.

Novartis Foundation and Microsoft Partner to Develop AI-Enabled Digital Health Tool for Early Leprosy Detection

The Novartis Foundation and Microsoft are partnering to develop an Artificial Intelligence (AI)-enabled Digital Health tool and a Leprosy Intelligent Image Atlas to aid in the early detection of leprosy
Press Release

BASEL, Switzerland, March 26, 2018 /3BL Media/  – The Novartis Foundation and Microsoft are partnering to develop an Artificial Intelligence (AI)-enabled Digital Health tool and a Leprosy Intelligent Image Atlas to aid in the early detection of leprosy. Over 200,000 people are diagnosed with leprosy every year. Brazil, India, and Indonesia account for about 80% of new cases. If untreated, patients are left with lifelong disabilities and are often stigmatized in their societies.

Novartis Joins the Global Chagas Disease Coalition and Also Announces First Multinational, Prospective, Randomized Study in People With Chronic Chagas Cardiomyopathy

Summary: 
  • Study is planned to assess efficacy and safety of Entresto® (sacubitril / valsartan) vs enalapril in 900 patients with chronic Chagas cardiomyopathy; recruitment is planned to commence within 2019
  • Chagas disease is a potentially life-threatening neglected disease, affecting approximately six million people worldwide1,2, mostly in Latin America; up to 30% of chronically infected people develop cardiac disorders3
  • Chagas cardiomyopathy is the most important clinical manifestation of the disease, resulting in the majority of morbidity and mortality4
  • The Global Chagas Disease Coalition is a collaborative alliance, which aims to increase awareness of Chagas disease and foster synergies in controlling the disease and promoting access to diagnosis and treatment5
Press Release
  • Study is planned to assess efficacy and safety of Entresto® (sacubitril / valsartan) vs enalapril in 900 patients with chronic Chagas cardiomyopathy; recruitment is planned to commence within 2019
  • Chagas disease is a potentially life-threatening neglected disease, affecting approximately six million people worldwide1,2, mostly in Latin America; up to 30% of chronically infected people develop cardiac disorders3
  • Chagas cardiomyopathy is the most important clinical manifestation of the disease, resulting in the majority of morbidity and mortality4
  • The Global Chagas Disease Coalition is a collaborative alliance, which aims to increase awareness of Chagas disease and foster synergies in controlling the disease and promoting access to diagnosis and treatment5

Novartis Receives FDA Approval for Egaten® for the Treatment of Fascioliasis, a Neglected Tropical Disease

Summary: 
  • Egaten is the only drug approved in the US for the treatment of people with fascioliasis and is currently the only treatment recommended by the WHO

  • Fascioliasis, commonly known as liver fluke infestation, is estimated to infect 2.4 million people globally1

  • Novartis has been donating Egaten to the WHO since 2005, helping to treat around 2 million patients in more than 30 countries

  • FDA approval reinforces the company’s commitment to reduce the burden of neglected tropical diseases including fascioliasis, leprosy and malaria

Press Release
  • Egaten is the only drug approved in the US for the treatment of people with fascioliasis and is currently the only treatment recommended by the WHO

  • Fascioliasis, commonly known as liver fluke infestation, is estimated to infect 2.4 million people globally1

  • Novartis has been donating Egaten to the WHO since 2005, helping to treat around 2 million patients in more than 30 countries

  • FDA approval reinforces the company’s commitment to reduce the burden of neglected tropical diseases including fascioliasis, leprosy and malaria

Sandoz Certified Global Top Employer 2019

Summary: 
  • Sandoz has been officially certified by the Top Employers Institute for its exceptional employee offerings globally
  • The Top Employers Institute is generally acknowledged as the global authority on recognizing excellence in people practices
  • This exclusive certification underlines our commitment to build a great place to work, based on a strong purpose-driven strategy
Press Release
  • Sandoz has been officially certified by the Top Employers Institute for its exceptional employee offerings globally
  • The Top Employers Institute is generally acknowledged as the global authority on recognizing excellence in people practices
  • This exclusive certification underlines our commitment to build a great place to work, based on a strong purpose-driven strategy

Government of Ghana Launches First of Its Kind Public-Private Partnership With Novartis to Improve Diagnosis and Treatment of People With Sickle Cell Disease

Summary: 
  • Memorandum of Understanding signed between Ministry of Health, Ghana Health Service, Sickle Cell Foundation of Ghana and global medicines company Novartis
  • Partnership to include the establishment of treatment guidelines, newborn screening, centers of excellence and the availability of accessible treatment options in line with the global standards of care
  • 15 000 babies are born with sickle cell disease every year in Ghana1
Press Release
  • Memorandum of Understanding signed between Ministry of Health, Ghana Health Service, Sickle Cell Foundation of Ghana and global medicines company Novartis
  • Partnership to include the establishment of treatment guidelines, newborn screening, centers of excellence and the availability of accessible treatment options in line with the global standards of care
  • 15 000 babies are born with sickle cell disease every year in Ghana1

Novartis Access Launches in Latin America

The program will be implemented in El Salvador through a partnership with the municipality of Santa Tecla and in Colombia through an agreement with the Colombian Red Cross to help migrant populations in the country.
Article

Novartis has signed an agreement with the municipality and the Patronato of Santa Tecla in El Salvador to distribute the Novartis Access portfolio to low-income patients with non-communicable diseases (NCDs) in this community. Beyond medications, the collaboration will also help train health professionals in NCD diagnosis and treatment, and promote education and awareness in the local community.

Novartis Social Business Joins Forces With THET to Train Hospital and Health Center Staff in Ethiopia

This new partnership responds to a request for training and capacity building from the Ethiopian Federal Ministry of Health to support its decentralization strategy for non-communicable disease services.
Article

We are pleased to announce that and The Tropical Health and Education Trust (THET) have come to an agreement to train hospital and health center staff at 60 sites across Ethiopia, ensuring that patients no longer need to travel long distances to seek treatment against non-communicable diseases (NCDs).

Pages

Subscribe to NYSE:NVS